2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors
Chawla N, Sayegh N, Tripathi N, Govindarajan A, Zengin Z, Phillip E, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal S, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2022, 21: 69-75. PMID: 36509613, DOI: 10.1016/j.clgc.2022.11.007.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall response rateTumor mutational burdenOverall survivalWorse OSPrimary diseaseMultivariate analysisMedian progression-free survivalImmune checkpoint inhibitor therapyInferior progression-free survivalPromoter mutationsWorse progression-free survivalCheckpoint inhibitor therapyMedian overall survivalImmune checkpoint inhibitorsTertiary cancer centerClinical prognostic factorsPrimary tumor siteTERT promoter mutationsCheckpoint inhibitorsInhibitor therapyLaboratory parametersPrognostic factorsCancer CenterFemale sex
2021
Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
Salgia NJ, Chehrazi‐Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine 2021, 10: 5671-5680. PMID: 34331372, PMCID: PMC8366095, DOI: 10.1002/cam4.4119.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAttitude of Health PersonnelCaliforniaCancer Care FacilitiesClinical Trials as TopicCommunicationFemaleHospitals, CommunityHumansIntersectoral CollaborationMaleMiddle AgedNeoplasmsOncologistsReferral and ConsultationSurveys and QuestionnairesTertiary Care CentersConceptsClinical trialsCommunity oncologistsTertiary centerTrial availabilityClinical trial availabilityTertiary cancer centerClinical trial enrollmentRegional tertiary centerCancer providersMost patientsTertiary referralMedical oncologistsReferral patternsTrial enrollmentCancer CenterTertiary practiceCancer carePatient referralMost oncologistsGeneral oncologistsCommon reasonClinical practiceOncologistsPatient careClinical expertiseBridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis.
Chehrazi-Raffle A, Salgia N, Hsu J, Zengin Z, Salgia S, Chawla N, Malhotra J, Dizman N, Muddasani R, Meza L, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal S. Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis. Journal Of Clinical Oncology 2021, 39: 1538-1538. DOI: 10.1200/jco.2021.39.15_suppl.1538.Peer-Reviewed Original ResearchCommunity oncologistsClinical trialsTertiary centerTrial availabilityCancer CenterCedars-Sinai Medical CenterHope Comprehensive Cancer CenterClinical trial availabilityTertiary cancer centerMajority of patientsClinical trial enrollmentComprehensive cancer centerSource of referralRegional tertiary centerSinai Medical CenterCommunity practicePT referralTertiary referralReferral patternsTrial enrollmentTertiary practiceCommunity care networksGeneral oncologistsMedical CenterCommon reason